- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02628574
Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab
A Phase 1 Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab in Adults With Advanced Solid Tumors
This study will be conducted in 5 parts (Parts A, B, C, D and E).
Monotherapy Treatment:
Subjects ≥18 years with advanced solid tumors will be enrolled in the study. Monotherapy dose escalation will be performed in Part A. Cycle 1 data from each cohort will be evaluated for safety and dose-limiting toxicities (DLTs) prior to dose escalation. Subjects will be assigned to a cohort in the order screening is completed. Dose will depend upon the cohort in which a patient is enrolled and cohorts will be dosed consecutively by ascending dose. Once the maximum tolerated dose (MTD) or maximum administered dose (MAD) has been identified, an expanded cohort will be enrolled (Part B).
Combination Treatment:
Subjects ≥18 years with advanced solid tumors will be enrolled in the study. Subjects will receive TRX518 in combination with gemcitabine (Part C), pembrolizumab (Part D), or nivolumab (Part E). Dose escalation will be performed for each part (Part Cesc, Part Desc, Part Eesc) and Cycle 1 data from each cohort will be evaluated for safety and dose-limiting toxicities (DLTs) prior to dose escalation. Subjects will be assigned to a cohort in the order screening is completed. Dose will depend upon the cohort in which a patient is enrolled and cohorts will be dosed consecutively by ascending dose. Once the maximum tolerated dose (MTD) or maximum administered dose (MAD) has been identified, an expanded cohort will be enrolled (Part Cexp, Part Dexp, Part Eexp).
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60637
- University of Chicago
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87131
- University of New Mexico Comprehensive Cancer Center
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44195
- Cleveland Clinic
-
Cleveland, Ohio, Estados Unidos, 44106
- University Hospitals
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15232
- University of Pittsburgh Medical Center
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37205
- Tennessee Oncology
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Advanced Solid Malignancies: Histologically documented metastatic or locally advanced, incurable solid malignancy (Parts A and B); histologically documented metastatic or locally advanced, incurable solid malignancy for which gemcitabine is clinically appropriate (e.g., non-small cell lung, breast, ovarian, pancreatic, and renal cancer); histologically documented metastatic or locally advanced, incurable solid malignancy for which pembrolizumab (Part D) or nivolumab (Part E) is approved. NOTE: Parts D and E only: Subject has either (1) received treatment with pembrolizumab or nivolumab for ≥4 months with a best response of stable disease and plans to continue treatment with either pembrolizumab or nivolumab in accordance with package insert; or (2) is not currently taking, but is eligible for treatment with, pembrolizumab or nivolumab in accordance with the approved indications for each as referenced in the package insert.
- Expected survival of at least 12 weeks after dosing.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
- Evidence of adequate organ function by standard laboratory tests.
- All female subjects of child bearing age must be either surgically sterile, postmenopausal for at least 1 year, or using an acceptable method of contraception. Adequate contraception for both male and female subjects must be used from the beginning of the screening period until at least 8 weeks after the last dose of study drug.
Exclusion Criteria:
- Hematologic malignancies or multiple myeloma.
- Known, clinically important cardiac or respiratory disease
- Any concomitant serious physical illness other than cancer (e.g., immune deficiency disease, bleeding disorder, etc.) within 1 year prior to dosing. No history of autoimmune disease.
- Active, uncontrolled infections within 7 days of study entry requiring systemic therapy.
- Evidence of progression of central nervous system (CNS) metastases or symptomatic CNS metastases within 30 days prior to dosing.
- History of known or suspected autoimmune disease with the specific exceptions of vitiligo, atopic dermatitis, or psoriasis not requiring systemic treatment. (Parts C, D and E only).
- Clinically-significant gastrointestinal disorders, such as perforation, gastrointestinal bleeding, or diverticulitis (Parts D and E only).
- Active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment (Parts D and E only).
- History of (non-infectious) pneumonitis that required steroids or current pneumonitis (Parts D and E only).
- History of interstitial lung disease (Parts D and E only).
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: TRX518 monotherapy (Parts A and B)
Subjects receive an assigned dose of TRX518 administered intravenously one time per week or one time per cycle on a 21-day cycle
|
comparison of different (ascending) doses of TRX518 monotherapy
|
Experimental: TRX518 with gemcitabine (Part C)
Subjects receive an assigned dose of TRX518 (dosed one time per cycle) intravenously administered in combination with gemcitabine (dosed two times per cycle) on a 21-day cycle
|
comparison of different (ascending) doses of TRX518 in combination with gemcitabine
|
Experimental: TRX518 with pembrolizumab (Part D
Subjects receive an assigned dose of TRX518 (dosed one time per cycle) intravenously administered in combination with pembrolizumab (dosed one time per cycle) on a 21-day cycle
|
comparison of different (ascending) doses of TRX518 in combination with pembrolizumab
|
Experimental: TRX518 with nivolumab (Part E)
Subjects receive an assigned dose of TRX518 (dosed two times per cycle) intravenously administered in combination with nivolumab (dosed two times per cycle) on a 28-day cycle
|
comparison of different (ascending) doses of TRX518 in combination with nivolumab
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Adverse events
Prazo: through 30 days post last dose
|
Any adverse change in health or side effect from the initiation of the study drug dose TRX518 monotherapy and TRX518 in combination with gemcitabine, pembrolizumab or nivolumab through completion or premature withdrawal
|
through 30 days post last dose
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
TRX518 peak concentration (Cmax)
Prazo: various timepoints through 1 week post dose
|
Observations of the distribution, duration of effects and chemical changes of TRX518 monotherapy and TRX518 in combination with gemcitabine, pembrolizumab or nivolumab in the body and the effects and routes of the body's elimination of TRX518
|
various timepoints through 1 week post dose
|
Time to peak concentration (Tmax)
Prazo: various timepoints through 1 week post dose
|
Observations of the distribution, duration of effects and chemical changes of TRX518 monotherapy and TRX518 in combination with gemcitabine, pembrolizumab or nivolumab in the body and the effects and routes of the body's elimination of TRX518
|
various timepoints through 1 week post dose
|
Area under the curve (AUC)
Prazo: various timepoints through 1 week post dose
|
Observations of the distribution, duration of effects and chemical changes of TRX518 monotherapy and TRX518 in combination with gemcitabine, pembrolizumab or nivolumab in the body and the effects and routes of the body's elimination of TRX518
|
various timepoints through 1 week post dose
|
RECIST assessment for evidence of antitumor activity
Prazo: up to 1 year
|
RECIST assessment to determine effects of TRX518 monotherapy and TRX518 in combination with gemcitabine, pembrolizumab or nivolumab on solid tumors.
|
up to 1 year
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Cadeira de estudo: Cyndi Sirard, MD, Leap Therapeutics, Inc.
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Efeitos Fisiológicos das Drogas
- Mecanismos Moleculares de Ação Farmacológica
- Agentes Anti-Infecciosos
- Antivirais
- Inibidores Enzimáticos
- Antimetabólitos, Antineoplásicos
- Antimetabólitos
- Agentes Antineoplásicos
- Agentes imunossupressores
- Fatores imunológicos
- Agentes Antineoplásicos Imunológicos
- Inibidores de Ponto de Verificação Imunológica
- Gemcitabina
- Nivolumabe
- Pembrolizumabe
Outros números de identificação do estudo
- TRX518-003
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Tumores Sólidos
-
Aadi Bioscience, Inc.RecrutamentoTumor Sólido Avançado | Tumor | Tumor SólidoEstados Unidos
-
Sorrento Therapeutics, Inc.RetiradoTumor Sólido | Tumor Sólido Recidivante | Tumor Refratário
-
Memorial Sloan Kettering Cancer CenterRecrutamentoTumor Sólido | Tumor Sólido, Adulto | Tumor Sólido, Não Especificado, AdultoEstados Unidos
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecrutamentoTumor Sólido | Tumor Sólido, Adulto | Tumor Sólido, Não Especificado, AdultoEstados Unidos, Porto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecrutamentoTumor Sólido | Tumor Sólido, Adulto | Tumor Sólido, Não Especificado, AdultoEstados Unidos, Porto Rico
-
RemeGen Co., Ltd.ConcluídoTumor Sólido Metastático | Tumor Sólido Localmente Avançado | Tumor sólido irressecávelAustrália
-
Yonsei UniversityMerck KGaA, Darmstadt, GermanyAtivo, não recrutandoTumor de Mutação Positiva PD-L1 | Tumor de Mutação Positiva EBV | Tumor Mutação MSI-H | Tumor de mutação POLE/POLD1Republica da Coréia
-
Baodong QinRecrutamento
-
National Health Research Institutes, TaiwanNational Cheng-Kung University HospitalRecrutamento
-
Elpiscience Biopharma, Ltd.Shanghai Junshi Bioscience Co., Ltd.RecrutamentoNeoplasias | Tumor Sólido | Tumor malignoChina
Ensaios clínicos em TRX518 monotherapy
-
Leap Therapeutics, Inc.Cancer Research Institute, New York CityConcluídoMelanoma Maligno Irressecável Estágio III ou Estágio IV ou Outras Neoplasias Tumorais SólidasEstados Unidos
-
Leap Therapeutics, Inc.Pfizer; Merck KGaA, Darmstadt, GermanyRescindidoTumores Sólidos | Câncer de Mama Triplo Negativo Avançado | Câncer de Mama Receptor Hormonal Avançado Positivo/Refratário Endócrino | Câncer de Próstata Avançado Resistente à Castração Metastático | Câncer de ovário avançado resistente à platinaEstados Unidos